Skip to content

Study on the relationship between gene polymorphism and antituberculosis drug-induced hepatotoxicity in Southwest China

Study on the relationship between gene polymorphism and antituberculosis drug-induced hepatotoxicity in Southwest China

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033048
Enrollment
Unknown
Registered
2020-05-18
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

liver injury group vs. non liver injury:Nil

Sponsors

Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed or clinically diagnosed as tuberculosis according to the health industry standard of the people's Republic of China - tuberculosis diagnosis (ws288-2017); 2. Patients between 18-75 years old; 3. Patients with normal liver function before admission; Four Patients who do not use drugs other than antituberculosis drugs with clear liver damage (such as paracetamol, indomethacin, cyclophosphamide, cisplatin, carboplatin, methotrexate, statins, estrogens, oral contraceptives, amiodarone, warfarin, chloromycetin, roxithromycin, ketoconazole, sulfanilamide, promethazine, cimetidine, etc.); paracetamol When phenol is used for cooling, the dosage of phenol in a single day should not exceed 4G or 2G. If phenol is used continuously for no more than 7 days, it can still be considered as a group; 5. Patients who sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with other diseases affecting liver function (such as HAV, HBV, HCV, HIV positive, fatty liver, alcoholic liver, liver cancer, liver cirrhosis, etc.); 2. Patients who do not use isoniazid and other first-line anti tuberculosis drugs for treatment; 3. The patients who were followed up for 6 months were not accepted.

Design outcomes

Primary

MeasureTime frame
GSTs;Blood concentration of anti-tuberculosis drugs;

Countries

China

Contacts

Public ContactXingxing Li

Sichuan People's Hospital Affiliated to University of Electronic Science and Technology

1690519531@qq.com+86 15334557571

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026